Course for Interventionist in training 2014.

ProEducar-SOLACI course presentations concluded on April 22, 2014 in Buenos Aires, Argentina

The V Edition of the “José Gabay” course of ProEducar – SOLACI,  be held as pre-conference activity at SOLACI, is aimed for interventionists in training all over America with the intention of strengthening the existing educational programs and, as well, provide a forum for them to integrate. // Read programe

More articles by this author

See the Presentations of the 13th ProEducar Fellows Course

  During SOLACI-SBHCI 2023, our traditional education program for young interventionists ProEducar Fellows Course was held.  Discover the presentations of the prestigious interventionists that made part of this 13th edition...

The best images of the 13th ProEducar Fellows Course at SOLACI-SBHCI 2023

Relive the best images of the 13th ProEducar Fellows Course held on August 2 during the SOLACI-SBHCI 2023 Congress in the URCA Room of...

13th ProEducar-SOLACI Fellows Course Held at SOLACI-SBHCI 2023

ProEducar-SOLACI Fellows Course continues to grow! For the thirteenth consecutive year, the traditional SOLACI course for fellow interventionists was held at SOLACI-SBHCI 2023. The course...

Teve lugar o 13º Curso de Fellows do ProEducar-SOLACI no Congresso SOLACI-SBHCI 2023

o Curso de Fellows do ProEducar-SOLACI continua crescendo! Pelo décimo terceiro ano consecutivo teve lugar o tradicional Curso da SOLACI para intervencionistas em formação...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...